Commercial Regeneron Q1 2026 net income falls 10% to $727m Pharmaceutical Business ReviewOn a non-GAAP basis, net income rose 12% to $1.04bn from $928m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaceutical Business Review On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. Read full story Post navigation Previous: Ray Therapeutics receives EMA PRIME status for gene therapyNext: Norgine gets first EU approval for WHIM syndrome therapy Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
